Diabetic Heart Disease: An Intricate Interplay of a Widespread Metabolic Disorder with the Cardiovascular System

Overview

Journal Curr Diabetes Rev

Publisher Bentham Science Publishers

Specialty Endocrinology

Date 2024 Jul 12

PMID 38994615

Authors

A S Kamakshi Shriya

Vaishnavi B Pawar

Acsah Annie Paul

Affiliations

Soon will be listed here.

Abstract

Diabetes is a chronic medical condition that causes high glycaemic levels, leading to damage to vital organs over time. It is a common disease worldwide, affecting around 422 million individuals living in middle- and low-income countries, which make up most of the population. Unfortunately, diabetes results in 1.5 million deaths annually. Diabetic patients are at a higher risk for developing cardiovascular conditions. Diabetic heart disease constitutes multiple genres, including diabetic cardiomyopathy, coronary artery disease, and heart failure. Hypoglycaemic agents aim to prevent these metabolic issues however some of these are cardiotoxic in nature. In contrast, other hypoglycaemic agents work beyond controlling glycaemic levels with their cardioprotective properties. Given that there is an alarming increase in diabetic heart disease cases universally, we have attempted to review the existing data on the topic and the effects of hypoglycaemic drugs on heart diseases.

References

Cheng A . Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Can J Diabetes. 2013; 37 Suppl 1:S1-3. DOI: 10.1016/j.jcjd.2013.01.009. View

Rajbhandari J, Fernandez C, Agarwal M, Yeap B, Pappachan J . Diabetic heart disease: A clinical update. World J Diabetes. 2021; 12(4):383-406. PMC: 8040078. DOI: 10.4239/wjd.v12.i4.383. View

Tomic D, Shaw J, Magliano D . The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022; 18(9):525-539. PMC: 9169030. DOI: 10.1038/s41574-022-00690-7. View

Glovaci D, Fan W, Wong N . Epidemiology of Diabetes Mellitus and Cardiovascular Disease. Curr Cardiol Rep. 2019; 21(4):21. DOI: 10.1007/s11886-019-1107-y. View

Rosengren A, Dikaiou P . Cardiovascular outcomes in type 1 and type 2 diabetes. Diabetologia. 2023; 66(3):425-437. PMC: 9840171. DOI: 10.1007/s00125-022-05857-5. View

Silander K, Tang H, Myles S, Jakkula E, Timpson N, Cavalli-Sforza L . Worldwide patterns of haplotype diversity at 9p21.3, a locus associated with type 2 diabetes and coronary heart disease. Genome Med. 2009; 1(5):51. PMC: 2689443. DOI: 10.1186/gm51. View

Goodarzi M, Rotter J . Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease. Circ Res. 2020; 126(11):1526-1548. PMC: 7250006. DOI: 10.1161/CIRCRESAHA.119.316065. View

Rodgers J, Jones J, Bolleddu S, Vanthenapalli S, Rodgers L, Shah K . Cardiovascular Risks Associated with Gender and Aging. J Cardiovasc Dev Dis. 2019; 6(2). PMC: 6616540. DOI: 10.3390/jcdd6020019. View

Wang Y, ONeil A, Jiao Y, Wang L, Huang J, Lan Y . Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants. BMC Med. 2019; 17(1):136. PMC: 6625042. DOI: 10.1186/s12916-019-1355-0. View

10.

Spanakis E, Golden S . Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep. 2013; 13(6):814-23. PMC: 3830901. DOI: 10.1007/s11892-013-0421-9. View

11.

Hong X, Lin J, Gu W . Risk factors and therapies in vascular diseases: An umbrella review of updated systematic reviews and meta-analyses. J Cell Physiol. 2018; 234(6):8221-8232. DOI: 10.1002/jcp.27633. View

12.

Kahl K, Stapel B, Frieling H . Link between depression and cardiovascular diseases due to epigenomics and proteomics: Focus on energy metabolism. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 89:146-157. DOI: 10.1016/j.pnpbp.2018.09.004. View

13.

Otfried Schwab K, Doerfer J, Hallermann K, Krebs A, Schorb E, Krebs K . Marked smoking-associated increase of cardiovascular risk in childhood type 1 diabetes. Int J Adolesc Med Health. 2008; 20(3):285-92. DOI: 10.1515/ijamh.2008.20.3.285. View

14.

Bagchi D, Sen C, Ray S, Das D, Bagchi M, Preuss H . Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutat Res. 2003; 523-524:87-97. DOI: 10.1016/s0027-5107(02)00324-x. View

15.

Abbasi F, Brown Jr B, Lamendola C, McLaughlin T, Reaven G . Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 2002; 40(5):937-43. DOI: 10.1016/s0735-1097(02)02051-x. View

16.

Adeva-Andany M, Martinez-Rodriguez J, Gonzalez-Lucan M, Fernandez-Fernandez C, Castro-Quintela E . Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metab Syndr. 2019; 13(2):1449-1455. DOI: 10.1016/j.dsx.2019.02.023. View

17.

Knowles J, Ashley E . Cardiovascular disease: The rise of the genetic risk score. PLoS Med. 2018; 15(3):e1002546. PMC: 5877829. DOI: 10.1371/journal.pmed.1002546. View

18.

Maahs D, Daniels S, de Ferranti S, Dichek H, Flynn J, Goldstein B . Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2014; 130(17):1532-58. DOI: 10.1161/CIR.0000000000000094. View

19.

Wali R, Henrich W . Chronic kidney disease: a risk factor for cardiovascular disease. Cardiol Clin. 2005; 23(3):343-62. DOI: 10.1016/j.ccl.2005.03.007. View

20.

Weiner D, Tighiouart H, Stark P, Amin M, MacLeod B, Griffith J . Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis. 2004; 44(2):198-206. DOI: 10.1053/j.ajkd.2004.04.024. View